IVD Clinical Trial Monitoring Should Be Higher Priority For Manufacturers
This article was originally published in The Gray Sheet
Executive SummaryDevelopers of in vitro diagnostics should make the monitoring of investigators a key part of their clinical trial protocols, speakers at the Oct. 26-27 Association Medical Diagnostics Manufacturers' annual meeting in Rockville, Maryland cautioned.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.